Ambrx Biopharma Cayman, Inc. Quarterly Liabilities and Equity in USD from Q4 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2020 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Liabilities and Equity for the quarter ending June 30, 2023 was $280M, a 54.8% increase year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2023 $280M +$99.1M +54.8% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $211M Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $147M -$82M -35.8% Dec 31, 2022 10-Q 2023-08-09
Q2 2022 $181M Jun 30, 2022 6-K 2022-08-29
Q4 2021 $229M +$95M +70.9% Dec 31, 2021 10-K 2023-03-30
Q4 2020 $134M Dec 31, 2020 20-F 2022-04-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.